EX-99.1 2 ea029904701ex99-1.htm PRESS RELEASE DATED JULY 23, 2026 Exhibit 99.1 Vaso Corporation Appoints Shaun McMeans to Board of Directors PLAINVIEW, N.Y., July 23, 2026 (GLOBE NEWSWIRE) -- Vaso Corporation (“Vaso”) (OTCQX: VASO), a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and proprietary medical products, today announced the appointment of Shaun McMeans to the Company’s Board of Directors, effective July 23, 2026. “We are pleased to welcome Shaun to Vaso’s Board of Directors,” said Dr. Jun Ma, President and Chief Executive Officer of Vaso Corporation. “Shaun brings substantial public company finance, accounting and operational leadership experience in the life sciences and technology sectors. We believe his background will be valuable to Vaso as we continue to execute our strategic initiatives and pursue long-term value for our stockholders.” Mr. McMeans currently serves as Chief Financial Officer of Nabsys, a life sciences technology company, where he leads finance and administrative functions. From 2012 through 2023, Mr. McMeans served as Chief Financial Officer of HTG Molecular Diagnostics, I…
Open exhibit ↗Current Report · Items 5.02, 9.01 · 8-K
Vaso Corporation
VASOOTCEQUITYCurrent
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements
Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. (d) On July 23, 2026, Shaun McMeans (64 years of age) was appointed by the Board of Directors as a Class III director of the Company, effective immediately. Mr.…
Press release in this filing
Vaso Corporation Appoints Shaun McMeans to Board of Directors →Company context
Vaso Corporation is a leading MedTech company with a diversified business portfolio in network and IT services, professional sales services and proprietary medical products. The Company operates through three principal business segments: IT, professional sales services and equipment.
Current securities
Disclosure sections
Item 5.02Item 5.02 - Departure/Election of Directors
Item 5.02. Departure of Directors or Certain Officers; Election
of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.
(d) On
July 23, 2026, Shaun McMeans (64 years of age) was appointed by the Board of Directors as a Class III director of the Company, effective
immediately.
Mr. McMeans currently serves as
Chief Financial Officer of Nabsys, a life sciences technology company, where he leads finance and administrative functions. From 2012
through 2023, Mr. McMeans served as Chief Financial Officer of HTG Molecular Diagnostics, Inc., a publicly traded life science tools and
diagnostics company. Prior to joining HTG Molecular Diagnostics, Mr. McMeans held senior finance and accounting roles with Securaplane
Technologies, Inc., Tatum LLC, The Long Companies, LXU Healthcare, Inc. and Burnham Holdings, Inc. Mr. McMeans received a B.S. in Accounting
from The Pennsylvania State University.
Mr. McMeans will serve as a member of the Board’s audit committee
and qualifies as a financial expert. There are no family relationships between Mr. McMeans and any director or other executive officer
of the Company nor are there any transactions between Mr. McMeans or any member of his immediate family and the Company or any of its
subsidiaries that would be reportable as a related party transaction under the rules of the United States Securities and Exchange Commission.
Further, there is no arrangement or understanding between Mr. McMeans and any other persons or entities pursuant to which Mr. McMeans
was appointed as a director of the Company. Upon his appointment to the Board, Mr. McMeans became entitled to be paid a pro-rated portion
of the Company's non-employee director compensation. He will also receive a one-time new director grant of 100,000 shares of Vaso common
stock.